share_log

尚高公司宣布签订证券购买协议,总收益为700万美金

Shanggao Corporation announced that it has signed a securities purchase agreement with a total revenue of 7 million US dollars.

PR Newswire ·  Jun 24 21:00

On June 20, 2024, Shangao Company (hereinafter referred to as "Shangao" or the "Company"; NASDAQ trading code: SISI; a technologically advanced medical and health products and services provider) announced today that it has signed a securities purchase agreement ("Agreement") with certain non-American investors ("Investors"). Under the Agreement, the Company will issue a maximum of 1,400,000 common shares ("Shares") to investors at a price of $5.00 per share through a private placement financing transaction ("Transaction"). Before deducting the usual fees, the total expected revenue from this offering is expected to be approximately $7,000,000. The former associate of the company purchased 1,000,000 common shares, while members of the company's management team and individual investors purchased 200,000 common shares respectively. The transaction and stock issuance are expected to be completed on July 31, 2024.

The company plans to use the proceeds from this offering for working capital and general corporate purposes to promote the implementation of its strategic initiatives.

The above-mentioned shares were issued through private placement in accordance with Regulation S of the Securities Act of 1933 and its revisions ("Securities Act"), and are not subject to registration requirements under the U.S. Securities Act of 1933, unless registered under valid registration statements or exemptions from registration provisions of applicable securities laws. They cannot be issued or sold in the United States unless registered or qualified under the securities laws of the relevant jurisdiction.

This press release does not constitute an offer to sell securities in the United States or any other jurisdiction or a solicitation of an offer to purchase securities. In such jurisdiction, such offer, solicitation, or sale is illegal until registered or qualified in accordance with the securities laws of the jurisdiction.

Ms. Jennifer, CEO of Shangao, said: "We are pleased to reach an agreement with the investors, as these funds will help promote the company's strategic growth and seize opportunities in the medical and health field. This financing demonstrates the confidence of our management and investors in our business strategy, business development, and growth prospects. Our operational, financing, and investment strategies have only one goal: to create long-term value for shareholders."

About Shanggao Corporation

Shangao (hereinafter referred to as "Shangao" or the "Company") aims to "focus on healthy living and improve the quality of life" by providing safe, efficient, and high-quality health and medical products and services to the society. So far, the company has developed 33 kinds of in vitro diagnostic reagents and related medical instruments, and produces and sells health and nutrition food. For more information about Shangao, please visit.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the amended Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements can be identified by the use of words such as “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “potential,” “project,” “intend,” “believe,” and similar expressions. These forward-looking statements are based on our current beliefs, expectations, and assumptions regarding future business performance, and may relate to, among other things, anticipated events, trends, amount of capital expenditures, future dividends, results of operations, anticipated growth, business prospects, credit ratings, provision for losses, income, expenses, plans and objectives of management, liquidity, and availability of funds. There is no assurance that any of these events or trends will occur or be achieved. Such forward-looking statements reflect the current views and assumptions of management with respect to future events, and are subject to certain risks and uncertainties. Actual results may differ materially from historical results or any forward-looking statements as a result of a variety of factors, including but not limited to the Company’s ability to obtain additional funding, the ability to maintain and grow business, variability of operating results, the ability to maintain and enhance their brand, the ability to develop and introduce new products and services, the ability to market and sell its products in jurisdictions where it is seeking required regulatory approvals, the ability to successfully integrate acquired companies, technologies, and assets into its product and service offerings, industry competition, general government regulation and economic conditions, the impact of the COVID-19 pandemic, reliance on key personnel, attracting, employing and retaining the necessary technical skills and experience to meet customer requirements and protect intellectual property rights. Shineco encourages you to review other factors that may affect its future performance in documents filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release are made as of the date hereof, and Shineco does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise, except as required under applicable law and regulation.

For additional information, please contact:

Shineco, Inc.
Email: secretary@shineco.tech
Phone: +86-010-68130220

Precept Investor Relations LLC
David J. Rudnick
Email: david.rudnick@preceptir.com
Phone: +1-646-694-8538

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment